Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

8.60
+0.01000.12%
Pre-market: 8.760.1646+1.91%06:16 EST
Volume:5.26M
Turnover:44.60M
Market Cap:1.19B
PE:-3.87
High:8.88
Open:8.53
Low:8.05
Close:8.59
52wk High:15.87
52wk Low:4.88
Shares:138.00M
Float Shares:107.00M
Volume Ratio:0.86
T/O Rate:4.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2247
EPS(LYR):-3.0800
ROE:-296.45%
ROA:-32.83%
PB:8.35
PE(LYR):-2.79

Loading ...

Morgan Stanley Initiates Eight Biotech Names, Rating Seven Overweight

Analyst Calls
·
Oct 20

Phase 3 Trial Success Might Change The Case For COMPASS Pathways Stock

Simply Wall St.
·
Oct 19

Cathie Wood’s ARK Investment buys 284K shares of Compass Pathways today

TIPRANKS
·
Oct 13

Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Oct 02

Compass Pathways Names Kelley Boucher Chief People Officer

Reuters
·
Sep 30

H.C. Wainwright Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

TIPRANKS
·
Sep 22

Compass Pathways Joins TD Cowen Novel Mechanisms in Neuropsychiatry Summit Fireside Chat

Reuters
·
Sep 16

As Trump Backs Psychedelics Research, FDA Weighs Safety and Access Standards

Reuters
·
Sep 15

Compass Pathways Launches ‘Change the Tune in Trd’ in the U.S. to Advance Hcp Understanding of Treatment-Resistant Depression at Psych Congress 2026

THOMSON REUTERS
·
Sep 15

Experts Urge FDA to Set Clear Safety and Access Standards for Psychedelic Drugs

Reuters
·
Sep 15

FDA to Hold Public Hearing on Psychedelic Drugs as Trump-Driven Push Gathers Pace

Reuters
·
Sep 15

Strata Mental Health Solutions awarded training grant by Compass Pathways

TIPRANKS
·
Sep 12

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval Comp360 Provider Training

THOMSON REUTERS
·
Sep 10

Compass Pathways Management Attends Investor Conference Fireside Chats in New York Week of Sept. 14

Reuters
·
Sep 10

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
Sep 10

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Sep 09

Compass Pathways Rises After One-Year Data for Psychedelic-Based Depression Drug

Reuters
·
Sep 09

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 Comp005 Trial Demonstrates Additional Benefit from Another Comp360 Dose in Part C Extending Durability Out to 1 Year

THOMSON REUTERS
·
Sep 09

Compass Pathways - Rolling Nda Submission Underway; Final Submission on Track for Q4

THOMSON REUTERS
·
Sep 09

Compass Pathways - Continue to Expect Commercial Launch in H1 2027

THOMSON REUTERS
·
Sep 09